Phase 4 Lupus Trial, Recruiting (NCT06875960)

Phase 4 Lupus Trial, Recruiting NCT06875960 Sponsor: Bristol-Myers Squibb Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT06875960 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You must have already completed one of two specific earlier studies (called IM011074 or IM011132) for the full required treatment period.
Your doctor must believe that you are likely to benefit from continuing treatment with the study drug (deucravacitinib).
You must have received the study drug within the last 60 days before joining this trial (exceptions may be possible — confirm with trial site).

Who may not be able to join:

You cannot join if your doctor feels you have any illness or health condition that would make this trial unsafe or unsuitable for you for any reason.
You cannot join if you currently have an active Tuberculosis (TB) infection.
There may be additional requirements not fully listed here, so confirm all eligibility details with the trial site.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06875960

Sponsor: Bristol-Myers Squibb

Phase: Phase 4

Status: Recruiting

Condition: Lupus

Trial contact: 855-907-3286

More information: https://clinicaltrials.gov/study/NCT06875960

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You must have already completed one of two specific earlier studies (called IM011074 or IM011132) for the full required treatment period.
Your doctor must believe that you are likely to benefit from continuing treatment with the study drug (deucravacitinib).
You must have received the study drug within the last 60 days before joining this trial (exceptions may be possible — confirm with trial site).

Who may not be able to join:

You cannot join if your doctor feels you have any illness or health condition that would make this trial unsafe or unsuitable for you for any reason.
You cannot join if you currently have an active Tuberculosis (TB) infection.
There may be additional requirements not fully listed here, so confirm all eligibility details with the trial site.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Bristol-Myers Squibb

Registry

ClinicalTrials.gov

Start date

24 February 2026

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants treated with BMS-986165

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov